“we’re right on target with getting back to our pre-Horizon capital structure by the end of this year.”

In context

“thought we'd be able to do when we made the acquisition. Overall, the rare disease portfolio of products, it's a very young portfolio of products where we're really just beginning to address the severe diseases that these drugs treat -- and whether it's TEPEZZA, UPLIZNA, KRYSTEXXA or TAVNEOS, these are going to be key growth driving products for us over the long haul, both in the U.S. and internationally. Peter Griffith: Speaking of youth, David, it's Peter here. Just a reminder that the transaction closed in October 23. So you mentioned a couple of years, it's been about 1.5 years, although so much has happened in the world that might feel like more than that. So we're delighted with the progress so far. As I mentioned in my remarks, we are right on target with pretax cost synergies, and we’re right on target with getting back to our pre-Horizon capital structure by the end of this year. So thanks for the question. Robert Bradway : Hi, Juliaan. The next question. Operator: Thank you David. Our next question comes from Jay Olson from Oppenheimer. Please go ahead, your line is open. Jay Olson: Hello, hey. Congrats on all the progress, and thank you for providing this update. Can you help us understand what to expect on the Bemarituzumab Phase III study readout coming up here in the second quarter? And how are you thinking about the market opportunity for [bema] (ph). Robert Bradway: Yes. Thanks, Jay, for the kind words. Bemarituzumab is our first-in-class fibroblast growth factor receptor IIb directed monoclonal antibody. This is a protein that appears on the surface of malignant gastric cancer cells with some frequency. And as you point out, we're conducting 2 prospective”